Journal of Renal Nutrition
Volume 17, Issue 5 , Pages 296-304 , September 2007

Gamma-Tocopherol and Docosahexaenoic Acid Decrease Inflammation in Dialysis Patients

  • Jonathan Himmelfarb, MD

      Affiliations

    • Division of Nephrology and Renal Transplantation, Maine Medical Center, Portland, Maine.
    • Maine Medical Center Research Institute, Scarborough, Maine.
    • Corresponding Author InformationAddress reprint requests to Jonathan Himmelfarb, MD, Division of Nephrology and Renal Transplantation, Maine Medical Center, 22 Bramhall St., Portland, ME 04102.
    • ,
  • Stephen Phinney, PhD

      Affiliations

    • Galileo Pharmaceuticals, Inc., Santa Clara, California.
    • ,
  • T. Alp Ikizler, MD

      Affiliations

    • Vanderbilt University School of Medicine, Nashville, Tennessee.
    • ,
  • Jane Kane, BA

      Affiliations

    • Maine Medical Center Research Institute, Scarborough, Maine.
    • ,
  • Ellen McMonagle, MS

      Affiliations

    • Maine Medical Center Research Institute, Scarborough, Maine.
    • ,
  • Guy Miller, MD, PhD

      Affiliations

    • Edison Pharmaceuticals, Inc., San Jose, California.

References 

  1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl):S112–S119
  2. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808
  3. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70
  4. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213–1217
  5. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933–1935
  6. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003;16:238–244
  7. Usberti M, Gerardi G, Bufano G, et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis. 2002;40:590–599
  8. Boaz M, Smetana S, Weinstein T, et al. Secondary Prevention With Antioxidants of Cardiovascular Disease in End-Stage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–1218
  9. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a controlled trial. Circulation. 2003;107:992–995
  10. Galli F, Floridi AG, Floridi A, Buoncristiani U. Accumulation of vitamin E metabolites in the blood of renal failure patients. Clin Nutr. 2004;23:205–212
  11. Himmelfarb J, Kane J, McMonagle E, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int. 2003;64:978–991
  12. Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids. 2003;38:813–819
  13. Galli F, Buoncristiani U, Conte C, Aisa C, Floridi A. Vitamin E in uremia and dialysis patients (Ann). N Y Acad Sci. 2004;1031:348–351
  14. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo by humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383–9387
  15. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–917
  16. Raatz SK, Bibus D, Thomas W, Kris-Etherton P. Total fat intake modifies plasma fatty acid composition in humans. J Nutr. 2001;131:231–234
  17. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Alp IT. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004;65:2371–2379
  18. Dupont WD, Plumer WD. PS power and sample size program available for free on the internet. Controlled Clin Trials. 1997;18:274
  19. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  20. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63–72
  21. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000;15:1207–1211
  22. Trey JE, Kushner I. The acute phase response and the hematopoietic system: the role of cytokines. Crit Rev Oncol Hematol. 1995;21:1–18
  23. Jiang Q, Elson-Schwab I, Courtmanch C, Ames BN. g-Tocopherol and its major metabolite, in contrast to a-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A. 2000;97:11495–11499
  24. Jiang Q, Lykkesfeldt J, Shigenaga MK, Shigeno ET, Christen S, Ames BN. Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med. 2002;33:1534–1542
  25. Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr. 2003;77:700–706
  26. Grammas P, Hamdheydari L, Benaksas EJ, et al. Anti-inflammatory effects of tocopherol metabolites. Biochem Biophys Res Commun. 2004;319:1047–1052
  27. Hensley K, Benaksas EJ, Bolli R, et al. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med. 2004;36:1–15
  28. Jiang Q, Ames BN. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J. 2003;17:816–822
  29. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113–1118
  30. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2:757–761
  31. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis (A randomized, double-blind, placebo-controlled trial). Ann Intern Med. 1999;130:554–562
  32. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71(Suppl):213S–223S
  33. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774–2783
  34. Bannenberg GL, Chiang N, Ariel A, et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol. 2005;174:4345–4355
  35. Ringbom T, Huss U, Stenholm A, et al. Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001;64:745–749
  36. Khalfoun B, Gruel Y, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human lymphocyte proliferation induced by allogenic cells. Transplant Proc. 1997;29:2397
  37. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004;350:29–37
  38. Di ML, Maffettone A, Cipriano P, et al. Is the erythrocyte membrane fatty acid composition a valid index of skeletal muscle membrane fatty acid composition?. Metabolism. 2000;49:1164–1166
  39. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukotrienes Essent Fatty Acids. 2003;69:393–399
  40. Felton CV, Stevenson JC, Godsland IF. Erythrocyte-derived measures of membrane lipid composition in healthy men: associations with arachidonic acid at low to moderate but not high insulin sensitivity. Metabolism. 2004;53:571–577
  41. Bistrian BR. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads lecture. J Parenter Enteral Nutr. 2003;27:168–175
  42. Iijima S, Otsuka F, Kikuchi H, et al. Oral supplementation with gamma-linolenic acid extracted from Mucor circinelloides improves the deformability of red blood cells in hemodialysis patients. Nephron. 2000;86:122–128
  43. Tsuzuki D, Sumino K, Yokoyama M. Analysis of 7-ketocholesterol in low density lipoprotein and fatty acid composition in erythrocyte membranes of patients on maintenance hemodialysis and healthy controls. Clin Chim Acta. 2000;295:155–168
  44. Friedman AN, Moe SM, Perkins SM, Li Y, Watkins BA. Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Am J Kidney Dis. 2006;47:1064–1071
  45. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): Randomized placebo-controlled trial. Lancet. 2000;356:1213–1218
  46. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A controlled trial. Circulation. 2003;107:992–995

 Support for this work was provided by Galileo Pharmaceuticals, Inc.

PII: S1051-2276(07)00112-4

doi: 10.1053/j.jrn.2007.05.011

Journal of Renal Nutrition
Volume 17, Issue 5 , Pages 296-304 , September 2007

Article Tools

* Image Usage & Resolution